Lino Biotech Exit

lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family offices. lino offers industry partners and researchers a unique way to study molecular interactions in living cells and crude biosystems.

Press releases

Press
16. March 2023

Successful exit for HTGF: Miltenyi Biotec acquires biosensor company lino Biotech

Zurich, March 16, 2023 – lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography®, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target respo
 
Press
17. November 2020

lino Biotech closes seed financing round and showcases a novel label-free biosensor platform for innovate modern drug screening

After almost a decade of initial invention and joint research on the Focal Molography technology at Roche, a leading player in the diagnostics and pharmaceutical area, and ETH Zurich as one of Europe’s most renowned research institutes, lino Biotech AG has licensed the technology to further develop and commercialize Focal Molography. The company has received 7-digit financing from lead-investors HTGF, Roche Ventures and several family offices. This broadly patented technology offers lab
 

Info & Contact

Address

Gloriastrasse 35
8092 Zürich

In portfolio

03. Mar 2020 – 02. Mar 2023

Sector

HTGF Manager

 
Dr. Martin Pfister, Principal / Authorized Signatory
Exit